New perspectives in antiemetic treatment

Area of Science:

• Pharmacology
• Oncology
• Neuroscience

Background:

• Chemotherapy-induced nausea and vomiting (CINV) remain significant challenges for patients despite advances in antiemetic therapy.
• Serotonin3 (5-HT3) receptor antagonists represent a major progress, but other targets within the serotonergic system are also implicated.
• The emetic reflex involves multiple receptor systems, including neurokinin1 (NK1) receptors and substance P.

Purpose of the Study:

• To review potential antiemetic effects beyond 5-HT3 receptor antagonism.
• To explore the role of other serotonin receptor subtypes (5-HT1A, 5-HT2) and serotonin synthesis inhibitors.
• To evaluate the potential of substance P antagonists and somatostatin analogues in managing CINV.

Main Methods:

• Review of existing literature on antiemetic mechanisms and drug targets.
• Analysis of animal studies on substance P antagonists.
• Consideration of clinical data for octreotide in gastrointestinal obstruction.

Main Results:

• Antiemetic effects can be achieved through various mechanisms, including 5-HT1A and 5-HT2 receptor agonism and serotonin synthesis inhibition.
• Substance P antagonists show a broad antiemetic profile in preclinical animal models.
• Octreotide demonstrates antiemetic effects in specific conditions but requires investigation for CINV.

Conclusions:

• Novel therapeutic strategies targeting the serotonergic system and substance P pathways are emerging for CINV.
• The clinical efficacy and safety of substance P antagonists and other novel agents need to be established.
• Future research will determine the utility of these drugs in the clinical management of chemotherapy-induced nausea and vomiting.